These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 25964164)

  • 21. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
    Ansell SM
    Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
    Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
    Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brentuximab vedotin for the treatment of CD30+ lymphomas.
    Foyil KV; Bartlett NL
    Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
    Haddley K
    Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
    Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
    Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
    Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
    Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
    N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
    Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
    Chen R; Chen B
    Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
    Rothe A; Sasse S; Goergen H; Eichenauer DA; Lohri A; Jäger U; Bangard C; Böll B; von Bergwelt Baildon M; Theurich S; Borchmann P; Engert A
    Blood; 2012 Aug; 120(7):1470-2. PubMed ID: 22786877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
    Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
    Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
    Illidge T; Bouabdallah R; Chen R; Gopal AK; Moskowitz CH; Ramchandren R; Shustov AR; Tilly H; Trippett TM; Gibb A; Grove LE; Advani R
    Leuk Lymphoma; 2015 Mar; 56(3):703-10. PubMed ID: 24913507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.
    Mei M; Thomas S; Chen R
    BioDrugs; 2014 Jun; 28(3):245-51. PubMed ID: 24258497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brentuximab vedotin in systemic T-cell lymphoma.
    Oki Y; Younes A
    Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
    Oak E; Bartlett NL
    Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
    Song Y; Guo Y; Huang H; Li W; Ke X; Feng J; Xu W; Miao H; Kinley J; Song G; Dai Y; Wang H; Zhu J
    Expert Rev Hematol; 2021 Sep; 14(9):867-875. PubMed ID: 34275403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.